- Paris, FRANCE / Cambridge, MA, USA
- 666-888-0000
- info@arianapharma.com
- info@arianapharma.com
- Paris, FRANCE / Cambridge, MA, USA
- Contact Us
Oct2014
Ariana Pharma joins the WIN Consortium as official technology partner
Leader in clinical big data analytics collaborates with global stakeholders in personalized cancer medicine. Partnership to accelerate translation of personalized medicine discoveries into widely available new standards of care for all cancer patients. Links: Download English PDF | Download French PDF Paris, France, and Cambridge, Massachusetts USA, 29 October 2014 – Ariana Pharma, developer of […]
Jul2014
EACR-23: Shorter multimarker signatures: a new tool to facilitate cancer diagnosis
KEM® Biomarker case study presented at EACR-23 this week showed that prognostic signatures generated by KEM® Biomarker have better or similar performances to other classification methods in terms of sensitivity and specificity while having significantly lower number of features in the models. 23rd Biennial Congress of the European Association for Cancer Research. From Basic Research […]
Jul2014
Presentations from WIN 2014 Symposium (Paris | June 23 – 24)
Young researchers from Ariana Pharma presented two posters at the recent WIN 2014 Symposium on breakthrough biomarker investigations and combined therapeutic approaches for precision cancer medicine, held in Paris on 23-24 June 2014. “P2.26: Computational biomarker models to predict response to lung cancer treatments from combined molecular data”, Marine Le Morvan, Maria del Pilar Schneider, […]
Feb2014
Les Echos Innovateurs: Bio-informatique : la FDA choisit le français Ariana Pharma
Une start-up française qui apporte un support technique à la Food and Drug Administration (FDA), c’est tout à fait dérogatoire. C’est pourtant le cas d’ Ariana Pharma, une petite société française spécialisée dans les applications pharmaceutiques du « data mining ». Links: Read online
Feb2014
Effective Design of Multi-Marker Diagnostic Tests for Personalized Medicine
Ariana Pharma releases a video to illustrate the use of its KEM® data mining technology in the effective design of multi-marker diagnostic tests for personalized medicine; KEM® identifies the shortest and most accurate signatures. The video is available on our Vimeo and YouTube channels or can be viewed below. One size doesn’t fit all! […]
Dec2013
BioPharmAnalyses interview – Ariana Pharma : trois nouveaux projets lancés en 2013 pour des solutions personnalisées contre le cancer
Ariana Pharma, société spécialiste de l’analyse des données cliniques et des tests diagnostiques pour la médecine personnalisée, vient d’annoncer le lancement du projet ExtempoRMN. A travers ce projet qui associe cette spin-off de l’Institut Pasteur au groupe d’instrumentation scientifique Bruker BioSpin, aux Hôpitaux universitaires de Strasbourg et au laboratoire Icube de l’université de Strasbourg, l’objectif […]
Dec2013
Biotech Finances audio interview – Ariana Pharma sélectionnée par deux consortia en oncologie
L’entreprise parisienne Ariana Pharma, spécialisée dans les outils informatiques d’aide à la décision clinique, a été retenue pour participer au projet alsacien ExtempoRMN. Celui-ci vise à développer une méthode innovante permettant d’établir le diagnostic des tissus cancéreux en temps réel. Quelques mois auparavant, Ariana Pharma était sélectionnée dans le cadre de l’essai clinique international Winther […]
Dec2013
Ariana Pharma announces ExtempoNMR, a new partnership with the potential to revolutionize brain cancer surgery
Neuro-oncology diagnostic tool aims to give surgeons the ability in ‘real-time’ to discriminate brain tumor tissue from surrounding healthy tissue.Radical new approach utilizes High Resolution Magic Angle Spinning Nuclear Magnetic Resonance technology Links: Download English PDF | Download French PDF Paris, France, and Cambridge, Massachusetts USA, 10 December 2013 – Ariana Pharma, developer of innovative […]
Sep2013
DDN News interview – Off to the data mines
When Ariana Pharma announced this summer that the WIN Consortium had chosen it to develop new personalized cancer medicine software through the consortium’s WINTHER trial, it wasn’t just a validation of Paris-based Ariana’s data management skills in life science, notes Dr. David Morley, Ariana’s vice president of computational technology — it was also a sign […]
Jul2013
EP Vantage interview – Ariana’s algorithms could deliver bespoke cancer therapy
The advent of targeted cancer therapies has necessitated the development of companion diagnostics to identify those patients whose genetic makeup will allow them to benefit. But a patient’s gene signature is only one factor of many capable of affecting their response to a treatment. There is a demand, says Mohammad Afshar, CEO of Ariana Pharma, […]